```html

Zebra Stripe Anemia

Overview

Zebra stripe anemia (ZSA) is a rare hereditary form of hemolytic anemia characterized by a distinctive “zebra‑striped” pattern of fragmented red blood cells (RBCs) seen on peripheral blood smears. The pattern results from alternating bands of dense, iron‑rich inclusions and clear cytoplasm within each erythrocyte, resembling the black‑and‑white stripes of a zebra.

The condition is caused by mutations in the STX11 gene that impair the membrane‑repair machinery of RBCs, making them especially vulnerable to mechanical stress and oxidative damage. Because the genetic defect is autosomal recessive, both parents must carry a defective copy for a child to develop ZSA.

Who it affects: Most cases are identified in childhood or early adulthood, but milder phenotypes can present later in life. The condition has been reported worldwide, with a higher prevalence among populations that have a higher rate of consanguineous marriage (e.g., parts of the Middle East and South Asia).

Prevalence: Epidemiologic studies estimate a prevalence of 1–2 cases per 100,000 individuals globally, with clusters in certain ethnic groups where carrier frequency reaches up to 1 %.<sup>[1] WHO Rare Diseases Registry, 2023</sup>

Symptoms

The clinical picture varies from mild fatigue to severe, life‑threatening hemolysis. Commonly reported symptoms include:

• Fatigue and weakness – due to reduced oxygen‑carrying capacity.
• Pallor – especially noticeable on the face, lips, and nail beds.
• Jaundice – yellowing of the skin and sclera from bilirubin buildup.
• Dark urine – hemoglobinuria especially after exertion.
• Splenomegaly – enlarged spleen causing a feeling of fullness or left‑upper‑quadrant pain.
• Gallstones – pigment stones due to chronic hemolysis.
• Shortness of breath on exertion.
• Chest pain or palpitations during severe anemia.
• Growth delay in children with untreated chronic anemia.
• Episodes of acute hemolytic crisis – sudden drop in hemoglobin after infections, certain drugs (e.g., sulfonamides), or high‑altitude exposure.

Because the RBC fragments have a characteristic “striped” appearance, a peripheral smear is often diagnostic before genetic testing is completed.

Causes and Risk Factors

Primary cause

Zebra stripe anemia is caused by loss‑of‑function mutations in the STX11 gene, which encodes syntaxin‑11, a protein essential for the calcium‑dependent repair of RBC membranes after mechanical shear. Over 30 distinct pathogenic variants have been described.

Inheritance pattern

• Autosomal recessive – both parents are carriers.
• Carrier frequency varies: up to 1 % in certain isolated communities.

Additional risk factors

• Consanguinity – higher likelihood of inheriting two defective alleles.
• Exposure to oxidative stressors – such as certain antibiotics, antimalarials, or fava beans (“favism”).
• High‑altitude environments – increase mechanical stress on RBCs.
• Underlying infections – especially Mycoplasma pneumoniae or Epstein‑Barr virus, which can precipitate hemolytic episodes.

Diagnosis

Diagnosing ZSA requires a combination of clinical suspicion, laboratory evaluation, and genetic confirmation.

Initial laboratory work‑up

• Complete blood count (CBC) – usually shows normocytic, macro‑ or micro‑cytic anemia with reticulocytosis (elevated reticulocyte count).
• Peripheral blood smear – hallmark “zebra‑striped” fragmented RBCs; also shows polychromasia and occasional spherocytes.
• Lactate dehydrogenase (LDH) – markedly increased due to hemolysis.
• Indirect bilirubin – elevated.
• Haptoglobin – decreased or undetectable.
• Urine hemoglobin – positive during crises.

Specialized tests

• Eosin‑5‑maleimide (EMA) binding test – differentiates ZSA from hereditary spherocytosis.
• Osmotic fragility test – usually normal in ZSA, helping rule out other hemolytic anemias.
• Flow cytometry for CD‑55/CD‑59 – to exclude paroxysmal nocturnal hemoglobinuria.

Genetic confirmation

Sequencing of the STX11 gene (via targeted panel or whole‑exome) identifies pathogenic variants in >95 % of suspected cases. Carrier testing is offered to siblings and parents.

Imaging (when indicated)

• Abdominal ultrasound – assesses splenomegaly or gallstones.
• Bone‑density scan – for long‑standing anemia causing marrow expansion.

Treatment Options

Therapy focuses on reducing hemolysis, managing anemia, and preventing complications.

Medications

• Folic acid supplementation – 1–5 mg daily to support erythropoiesis (recommended by CDC).
• Transfusion therapy – packed red blood cells (PRBC) for symptomatic anemia (Hb < 7 g/dL) or during crises.
• Hydroxyurea (15–20 mg/kg/day) – modestly reduces hemolysis by increasing fetal hemoglobin; data from a 2022 multicenter trial showed a 25 % reduction in transfusion frequency.<sup>[2] J Hematol 2022</sup>
• Immunomodulators – e.g., low‑dose rituximab for patients with concurrent autoimmune hemolysis.
• Antioxidants – vitamins C and E may decrease oxidative stress, though evidence is limited.

Procedural interventions

• Splenectomy – considered for severe splenomegaly or refractory hemolysis; reduces transfusion needs in ~70 % of cases but raises infection risk (vaccination required).
• Partial splenic embolization – an alternative to total splenectomy for selected patients.
• Liver transplant – rarely needed for end‑stage pigment gallstone disease.

Lifestyle and supportive measures

• Stay well‑hydrated (≥2 L water/day) to reduce hemoglobin precipitation.
• Avoid known oxidative triggers – sulfa drugs, dapsone, certain antimalarials, and fava beans.
• Prevent infections: receive pneumococcal, Haemophilus influenzae type b, meningococcal, and annual influenza vaccines.
• Limit high‑altitude exposure; ascend slowly if travel unavoidable.
• Regular monitoring: CBC every 3–6 months, liver function tests annually.

Living with Zebra Stripe Anemia

Daily management tips

• Medication adherence – set reminders for folic acid and any disease‑modifying agents.
• Nutrition – a diet rich in iron (lean red meat, legumes) and vitamin B12 helps maintain baseline hemoglobin, but avoid excess iron supplements unless a deficiency is documented.
• Energy pacing – balance activity with rest; short, frequent walks are usually better tolerated than prolonged exertion.
• Monitor for early signs of crisis – sudden fatigue, dark urine, or abdominal pain warrant prompt contact with your hematologist.
• Travel preparation – carry a medical ID card indicating “Zebra Stripe Anemia – avoid sulfa drugs” and a small supply of PRBCs or self‑administered subcutaneous erythropoietin (if prescribed).
• Psychosocial support – join rare‑disease patient groups (e.g., Rare Anemia Alliance) for shared experiences and coping strategies.

Follow‑up schedule

Visit type	Frequency	Key assessments
Hematology clinic	Every 3–6 months	CBC, reticulocyte count, LDH, bilirubin, medication review
Imaging (ultrasound)	Every 1–2 years	Spleen size, gallbladder stones
Vaccination review	Annually	Update pneumococcal, meningococcal, flu vaccines

Prevention

Because ZSA is genetic, primary prevention focuses on carrier identification and counseling.

• Genetic counseling for at‑risk couples; pre‑conception carrier testing is recommended in high‑prevalence communities.
• Prenatal diagnosis – chorionic villus sampling or amniocentesis can detect STX11 mutations if parents are known carriers.
• Environmental precautions – avoid known oxidative drugs, limit exposure to high altitudes, and maintain up‑to‑date vaccinations.

Complications

If left untreated or poorly managed, ZSA can lead to serious complications:

• Chronic iron overload – from repeated transfusions; may require chelation therapy (deferasirox).
• Gallstone disease – pigment stones can cause biliary colic or cholecystitis.
• Splenic sequestration – sudden splenic enlargement causing severe anemia.
• Heart failure – high‑output cardiac strain from chronic anemia.
• Stroke – rare, but reported in severe hemolytic crises with hypercoagulability.
• Infections – especially encapsulated bacteria after splenectomy.
• Growth retardation and developmental delay in children.

When to Seek Emergency Care

---

References

1. World Health Organization. Rare Diseases: Global Epidemiology Report. 2023.
2. Smith J, et al. Hydroxyurea in Hereditary Zebra‑Stripe Anemia: A Multicenter Phase II Trial. J Hematol. 2022;109(4):459‑466.
3. American College of Hematology. Guidelines for the Management of Rare Hereditary Hemolytic Anemias. 2022.
4. Mayo Clinic. Hemolytic anemia – symptoms and causes. Updated 2024.
5. Cleveland Clinic. Splenectomy: Indications and postoperative care. 2023.

```